Loading
A phase 3 trial of Relcobatinib run by Enliven Therapeutics, not yet recruiting.
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs is a phase 3 interventional study registered as NCT07905183 by Enliven Therapeutics, with 450 participants planned, started 2026-12-31. Conditions recorded: Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive and Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML. Interventions recorded: ELVN-001 and TKI.
Shares Relcobatinib, Enliven Therapeutics, Chronic myeloid leukaemia (CML), Acute myeloid leukaemia and the tag pipeline.
Shares Relcobatinib, Enliven Therapeutics, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute myeloid leukaemia and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/